AFRM vs BRK-B

AFRM's Piotroski F-Score of 7/9 indicates strong operational health, but the absence of an Altman Z-Score raises concern about bankruptcy risk, particularly given a high Debt/Equity ratio of 2.59. The stock trades at a premium valuation (P/E 57.88 vs. sector average 30.46) despite mixed earnings quality, with recent Q/Q EPS growth at +213% but year-over-year EPS down 5.3%. Insider selling totaling $56.66M in the last six months signals bearish sentiment from management. While revenue and earnings growth remain robust (29.6% and 59.3% YoY), the lack of cash flow data and high leverage undermine financial stability. The current price of $46.88 is significantly above both the Graham Number ($13.95) and intrinsic value estimate ($23.9), suggesting a substantial valuation premium driven by growth expectations.

The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.